Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Thalia Therap. (THAT) Share Price

Price 0.675p on 12-08-2026 at 18:25:10
Change 0.00p 0%
Buy 0.70p
Sell 0.65p
Last Trade: Buy 285.00 at 0.70p
Day's Volume: 285
Last Close: 0.675p
Open: 0.675p
ISIN: GB00BYW8QM32
Day's Range 0.675p - 0.675p
52wk Range: 0.414p - 0.90p
Market Capitalisation: £11.99m
VWAP: 0.70p
Shares in Issue: 1.78b

Thalia Therap. (THAT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 285 0.70p SI Trade
08:56:41 - 12-Aug-26
Sell* 35,000 0.6555p Ordinary
16:08:58 - 11-Aug-26
Sell* 6,557 0.6716p Ordinary
15:09:15 - 11-Aug-26
Buy* 211 0.70p SI Trade
09:15:15 - 11-Aug-26
Sell* 1,666 0.65p SI Trade
09:15:15 - 11-Aug-26
Buy* 3,119 0.70p SI Trade
16:04:20 - 10-Aug-26
Buy* 2,880 0.70p SI Trade
15:31:49 - 10-Aug-26
Buy* 6,773 0.70p Ordinary
15:31:49 - 10-Aug-26
Sell* 110,000 0.65p Ordinary
12:27:22 - 10-Aug-26
Buy* 400 0.70p SI Trade
11:17:14 - 10-Aug-26
See more Thalia Therap. trades

Thalia Therap. (THAT) Share Price History

Time period:
to
Date Open High Low Close Volume
12th Aug 2026 (Wed) 0.675 0.675 0.675 0.675 285
11th Aug 2026 (Tue) 0.675 0.675 0.675 0.675 43,434
10th Aug 2026 (Mon) 0.675 0.675 0.675 0.675 194,105
7th Aug 2026 (Fri) 0.675 0.675 0.675 0.675 203,029
6th Aug 2026 (Thu) 0.675 0.675 0.675 0.675 81,799
5th Aug 2026 (Wed) 0.675 0.675 0.675 0.675 74,664
4th Aug 2026 (Tue) 0.675 0.675 0.675 0.675 202,941
3rd Aug 2026 (Mon) 0.675 0.675 0.675 0.675 238,579
31st Jul 2026 (Fri) 0.675 0.70 0.70 0.675 345,145
30th Jul 2026 (Thu) 0.675 0.675 0.675 0.675 105,713
29th Jul 2026 (Wed) 0.675 0.675 0.675 0.675 730,658
28th Jul 2026 (Tue) 0.70 0.70 0.675 0.675 996,585
27th Jul 2026 (Mon) 0.70 0.70 0.70 0.70 205,669
24th Jul 2026 (Fri) 0.70 0.70 0.70 0.70 615,824
23rd Jul 2026 (Thu) 0.70 0.70 0.70 0.70 3,909,372
22nd Jul 2026 (Wed) 0.65 0.70 0.65 0.70 3,165,671
21st Jul 2026 (Tue) 0.65 0.65 0.65 0.65 1,516,729
20th Jul 2026 (Mon) 0.65 0.65 0.65 0.65 313,251
17th Jul 2026 (Fri) 0.65 0.65 0.65 0.65 10,484,667
16th Jul 2026 (Thu) 0.65 0.65 0.65 0.65 868,813
15th Jul 2026 (Wed) 0.65 0.65 0.65 0.65 865,580
14th Jul 2026 (Tue) 0.65 0.65 0.65 0.65 340,962
13th Jul 2026 (Mon) 0.65 0.65 0.65 0.65 757,212
See more Thalia Therap. price history

Thalia Therap. (THAT) Regulatory News

Date Source Headline
4th Aug 2026 10:30 am RNS Holding(s) in Company
31st Jul 2026 11:07 am RNS Total Voting Rights
29th Jul 2026 3:33 pm RNS Holding(s) in Company
23rd Jul 2026 9:25 am RNS Grant of Director Share Options
21st Jul 2026 5:23 pm RNS Holding(s) in Company
21st Jul 2026 5:21 pm RNS Holding(s) in Company
21st Jul 2026 11:36 am RNS Holding(s) in Company
17th Jul 2026 11:21 am RNS Result of AGM and Completion of Acquisition
17th Jul 2026 7:00 am RNS AGM Statement
24th Jun 2026 3:21 pm RNS Posting of Annual Report and Notice of AGM
See more Thalia Therap. regulatory news

Thalia Therap. (THAT) Share News

UK shareholder meetings calendar - next 7 days

10th Jul 2026 13:43

Read More

TRADING UPDATES: Tullow Oil makes partial notes repayment

24th Jun 2026 13:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

LONDON MARKET MIDDAY: Stocks mixed but no "contagion" from US sell-off

24th Jun 2026 11:59

(Alliance News) - The FTSE 100 was higher at midday on Wednesday, boosted by Segro after it rejected an "opportunistically timed" takeover proposal, and as the US and Iran reportedly prepare to restart 'technical talks'. Read More

IN BRIEF: Thalia Therapeutics eyes adding microRNA therapeutic asset

23rd Jun 2026 20:20

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at GBP1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at GBP7,264 versus GBP7,282. Research and development costs fall to GBP214,120 from GBP390,387 and general and administration costs rise to GBP1.0 million from GBP837,996. "Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company's portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company," says Chief Executive David Solomon. Read More

EARNINGS AND TRADING: Asia Strategic Holdings revenue declines

9th Jun 2026 18:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

See more Thalia Therap. news
FTSE 100 Latest
Value10,833.15
Change-11.04

Login to your account

Forgot Password?

Not Registered